By Counterforce Health Team in Tegsedi (inotersen) —

Tegsedi (Inotersen) Approval with Blue Cross Blue Shield of Texas: Complete Guide with Forms and Appeal Scripts

Quick Answer: Blue Cross Blue Shield of Texas requires prior authorization, REMS program enrollment, and documented step therapy failure for Tegsedi (inotersen) coverage. Your doctor submits the PA request through the provider portal with genetic testing, treatment history, and REMS enrollment proof. If denied, you have 60 days to appeal internally, then can request an Independent Review Organization (IRO) review within 45 days. Start by calling the number on your insurance card to confirm your specific plan's requirements.

Table of Contents

Coverage Basics

Is Tegsedi Covered by Blue Cross Blue Shield of Texas?

Yes, but with important conditions. Blue Cross Blue Shield of Texas (BCBSTX) covers Tegsedi (inotersen) as a specialty medication on their formulary, but requires prior authorization, step therapy compliance, and REMS program enrollment before dispensing.

Key Coverage Requirements:

  • Prior authorization mandatory for all BCBSTX plans
  • Maximum 4 syringes per 28-day period
  • Must use in-network specialty pharmacy only
  • REMS program enrollment required for both patient and prescriber
  • Regular laboratory monitoring mandated
Important: Tegsedi was discontinued by the manufacturer in 2024, but existing patients can often continue therapy through 2026 under legacy coverage agreements.

Which BCBSTX Plans Cover Tegsedi?

All BCBSTX commercial plans include Tegsedi on their specialty drug formulary, including:

  • Individual and family marketplace plans
  • Employer-sponsored group plans
  • Performance and Enhanced plan tiers

Coverage specifics may vary by plan type, so verify your exact benefits by calling the member services number on your insurance card.

Prior Authorization Process

Step-by-Step: Fastest Path to Approval

  1. Confirm Diagnosis and Testing (Patient + Doctor)
    • Genetic testing confirming pathogenic TTR mutation
    • Clinical documentation of hATTR polyneuropathy symptoms
    • Timeline: 1-2 weeks for genetic results
  2. Complete REMS Enrollment (Doctor + Patient)
    • Provider enrolls in Tegsedi REMS program
    • Patient completes REMS education and consent
    • Timeline: 1-3 business days for processing
  3. Document Step Therapy (Doctor)
    • Records of failed/contraindicated first-line therapies (Onpattro, Amvuttra)
    • Clinical rationale if step therapy exception needed
    • Timeline: Immediate if records exist
  4. Submit Prior Authorization (Doctor)
    • Complete PA request via BCBSTX provider portal
    • Include all supporting documentation
    • Timeline: Same day submission
  5. BCBSTX Review (Insurance)
    • Standard review: 15 business days
    • Expedited review: 72 hours (if urgent)
    • Timeline: Varies by request type
  6. Specialty Pharmacy Coordination (Patient + Pharmacy)
    • Prescription sent to approved specialty pharmacy
    • Benefit verification and patient education
    • Timeline: 2-3 days for first shipment

Required Documentation Checklist

  • Genetic test results showing pathogenic TTR mutation
  • Clinical notes documenting hATTR polyneuropathy diagnosis
  • Treatment history with first-line therapies
  • REMS program enrollment confirmation
  • Baseline laboratory values (platelet count, kidney function)
  • Medical necessity letter from prescribing physician

REMS Program Requirements

The FDA requires both patients and prescribers to enroll in Tegsedi's Risk Evaluation and Mitigation Strategy (REMS) program due to serious safety risks.

Patient Requirements

  • Complete REMS education about thrombocytopenia and kidney risks
  • Sign informed consent acknowledging safety monitoring needs
  • Commit to required laboratory monitoring schedule

Prescriber Requirements

  • Complete REMS training and certification
  • Agree to monitor patients per protocol
  • Report adverse events as required

Ongoing Monitoring Schedule

  • Platelet counts: Weekly for first 8 weeks, then every 2 weeks
  • Kidney function: Every 2 weeks throughout treatment
  • Clinical assessments: Regular follow-up visits per prescriber judgment
Critical: Failure to maintain REMS compliance will result in therapy discontinuation and coverage termination.

Step Therapy and Medical Necessity

BCBSTX typically requires documented trial and failure of first-line hATTR treatments before approving Tegsedi.

Preferred First-Line Therapies

  1. Onpattro (patisiran) - siRNA therapy
  2. Amvuttra (vutrisiran) - newer siRNA option

Medical Necessity Criteria

Your doctor must document:

  • Confirmed hATTR amyloidosis with polyneuropathy
  • Inadequate response to preferred therapies after adequate trial
  • OR contraindications/intolerance to first-line options
  • Clinical rationale for Tegsedi specifically

Step Therapy Exception Requests

If you haven't tried first-line therapies, your doctor can request an exception by documenting:

  • Medical contraindications to preferred drugs
  • Previous severe adverse reactions
  • Clinical factors making Tegsedi the most appropriate choice

Specialty Pharmacy Requirements

BCBSTX requires Tegsedi to be dispensed only through their in-network specialty pharmacy network.

Why Specialty Pharmacy is Required

  • Complex handling and storage requirements
  • REMS program compliance monitoring
  • Patient education and injection training
  • Coordination with required laboratory monitoring

What to Expect

  • Benefit verification: Pharmacy confirms coverage and copay
  • Patient education: Training on injection technique and safety
  • Delivery coordination: Home delivery with temperature monitoring
  • Ongoing support: 24/7 pharmacist access for questions
Note: Attempting to fill Tegsedi at a retail pharmacy will result in coverage denial.

Understanding Costs and Coverage Gaps

Typical Cost Structure

  • Copay plans: Fixed amount per prescription (varies by tier)
  • Coinsurance plans: Percentage of drug cost (typically 10-40% for specialty drugs)
  • Deductible: May apply before copay/coinsurance kicks in

Financial Assistance Options

  1. Manufacturer Support: Limited programs available for legacy patients (verify with Ionis Connect)
  2. Foundation Grants: HealthWell Foundation, Patient Access Network Foundation
  3. State Programs: Texas may have additional assistance programs
Important: Government insurance (Medicare, Medicaid) typically cannot use manufacturer copay assistance programs.

Appeals Process in Texas

Internal Appeal (First Level)

  • Deadline: 60 days from denial notice
  • Timeline: BCBSTX has 30 days for pre-service requests, 60 days for post-service
  • How to file: Submit appeal form with supporting documentation

Independent Review Organization (IRO)

Texas law provides strong external appeal rights for specialty drug denials.

IRO Process for Drug Denials:

  • When to file: After internal appeal denial, within 45 days
  • Timeline: 3 calendar days for prescription drug reviews
  • Cost: Free to patient (insurer pays IRO fees)
  • Decision: Binding on BCBSTX

Expedited Appeals

For urgent medical situations:

  • Internal expedited: 72-hour decision
  • IRO expedited: 3-day decision (concurrent with internal if life-threatening)
Texas Resource: Call Texas Department of Insurance at 866-554-4926 for IRO assistance.

Common Denial Reasons and Solutions

Denial Reason Solution Documents Needed
Missing REMS enrollment Complete enrollment before resubmission REMS confirmation letter
No step therapy documentation Provide treatment history Medical records, pharmacy records
Insufficient medical necessity Enhanced clinical documentation Detailed physician letter, genetic testing
Wrong specialty pharmacy Transfer to in-network pharmacy New prescription to approved pharmacy
Missing lab monitoring plan Submit monitoring protocol Lab schedule, baseline results

Troubleshooting and Support

When Your Doctor's Office Needs Help

Provider Support Line: Contact BCBSTX provider services for:

  • Prior authorization form assistance
  • Coverage verification questions
  • Appeal submission guidance

When You Need Direct Help

Member Services: Call the number on your insurance card for:

  • Benefit verification
  • Appeal status checks
  • Specialty pharmacy network information

Advocacy Resources

Counterforce Health specializes in turning insurance denials into successful appeals for complex medications like Tegsedi. Their platform analyzes denial letters and creates evidence-backed appeals tailored to your specific plan's requirements, potentially saving months of back-and-forth with insurers.

FAQ: Your Most Common Questions

Q: How long does BCBSTX prior authorization take for Tegsedi? A: Standard review takes up to 15 business days. Expedited review (for urgent cases) takes 72 hours. Your doctor can request expedited review if delays would jeopardize your health.

Q: What if Tegsedi isn't on my specific plan's formulary? A: All BCBSTX plans include Tegsedi as a specialty medication, but coverage levels vary. Contact member services to verify your specific plan's coverage and copay structure.

Q: Can I get an expedited appeal in Texas? A: Yes. Texas allows expedited internal appeals (72 hours) and expedited IRO reviews (3 days) for urgent medical situations. Clearly state the urgency in your appeal request.

Q: Does step therapy apply if I tried other treatments outside Texas? A: Yes, treatment history from other states counts toward step therapy requirements. Ensure your doctor includes all relevant medical records in the PA request.

Q: What happens if my appeal is denied? A: After internal appeal denial, you can request an Independent Review Organization (IRO) review. The IRO decision is binding on BCBSTX and must be completed within 3 days for drug denials.

Q: Why was my prescription transferred to a specialty pharmacy? A: BCBSTX requires Tegsedi to be dispensed through specialty pharmacies due to REMS requirements, complex handling needs, and patient education requirements. This is mandatory for coverage.

Q: How do I check my appeal status? A: Call BCBSTX member services or log into your member portal. Keep your appeal reference number handy for status checks.

Q: Can I continue Tegsedi while appealing a denial? A: Generally no, unless you're already on therapy and request continuation of benefits during appeal. This must be requested quickly after receiving the denial notice.

For comprehensive support with complex prior authorizations and appeals, Counterforce Health offers specialized assistance in navigating insurance requirements for rare disease medications.

Sources & Further Reading

Disclaimer: This information is for educational purposes only and does not constitute medical or legal advice. Insurance coverage varies by plan and individual circumstances. Always verify current requirements with your insurance company and consult your healthcare provider for medical decisions. For complaints or additional help with Texas insurance issues, contact the Texas Department of Insurance at 1-800-252-3439.

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.